Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses
dc.contributor.author | Wurtman, Richard | |
dc.contributor.author | Sakamoto, Joshimasa | |
dc.contributor.buuauthor | Cansev, Mehmet | |
dc.contributor.buuauthor | Ulus, İsmail Hakkı | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | D-5340-2015 | tr_TR |
dc.contributor.researcherid | M-9071-2019 | tr_TR |
dc.contributor.scopusid | 8872816100 | tr_TR |
dc.contributor.scopusid | 7004271086 | tr_TR |
dc.date.accessioned | 2021-11-09T06:23:11Z | |
dc.date.available | 2021-11-09T06:23:11Z | |
dc.date.issued | 2008-01 | |
dc.description.abstract | Although cognitive performance in humans and experimental animals can be improved by administering omega-3 fatty acid docosahexaenoic acid (DHA), the neurochemical mechanisms underlying this effect remain uncertain. In general, nutrients or drugs that modify brain function or behavior do so by affecting synaptic transmission, usually by changing the quantities of particular neurotransmitters present within synaptic clefts or by acting directly on neurotransmitter receptors or signal-transduction molecules. We find that DHA also affects synaptic transmission in mammalian brain. Brain cells of gerbils or rats receiving this fatty acid manifest increased levels of phosphatides and of specific presynaptic or postsynaptic proteins. They also exhibit increased numbers of dendritic spines on postsynaptic neurons. These actions are markedly enhanced in animals that have also received the other two circulating precursors for phosphatidylcholinc, uridine (which gives rise to brain uridine diphosphate and cytidine triphosphate) and choline (which gives rise to phosphocholine). The actions of DHA acre reproduced by eicosapentaenoic acid, another omega-3 compound, but not by omega-6 fatty acid arachidonic acid. Administration of circulating phosphatide precursors can also increase neurotransmitter release (acetylcholine, dopamine) and affect animal behavior. Conceivably, this treatment might have use in patients with the synaptic loss that characterizes Alzheimer's disease or other neurodegenerative diseases or occurs after stroke or brain injury. | en_US |
dc.description.sponsorship | Center for Brain Sciences and Metabolism Charitable Trust | en_US |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) (R01 MH028783) | en_US |
dc.identifier.citation | Cansev, M. vd. (2008). ''Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses''. Alzheimers & Dementia, 4(1), Supplement 1, S153-S168. | en_US |
dc.identifier.endpage | 168 | tr_TR |
dc.identifier.issn | 1552-5260 | |
dc.identifier.issn | 1552-5279 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 18631994 | tr_TR |
dc.identifier.scopus | 2-s2.0-38049116118 | tr_TR |
dc.identifier.startpage | 153 | tr_TR |
dc.identifier.uri | https://www.sciencedirect.com/science/article/abs/pii/S1552526007006280 | |
dc.identifier.uri | https://doi.org/10.1016/j.jalz.2007.10.005 | |
dc.identifier.uri | http://hdl.handle.net/11452/22588 | |
dc.identifier.volume | 4 | tr_TR |
dc.identifier.wos | 000252699700027 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | CPCIS | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | Alzheimers & Dementia | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Phosphatide | en_US |
dc.subject | Uridine | en_US |
dc.subject | Docosahexaenoic acid | en_US |
dc.subject | Precursor | en_US |
dc.subject | Synaptic membrane | en_US |
dc.subject | Dendritic spine | en_US |
dc.subject | Alzheimer's disease | en_US |
dc.subject | Polyunsaturated fatty-acids | en_US |
dc.subject | Ctp-phosphocholine cytidylyltransferase | en_US |
dc.subject | Dependent nucleoside transport | en_US |
dc.subject | Phospholipase-c treatment | en_US |
dc.subject | Long-term potentiation | en_US |
dc.subject | Rat-liver microsomes | en_US |
dc.subject | Hamster ovary cells | en_US |
dc.subject | Cdp-choline levels | en_US |
dc.subject | Docosahexaenoic acid | en_US |
dc.subject | Dendritic spines | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject.emtree | Acetylcholine | en_US |
dc.subject.emtree | Arachidonic acid | en_US |
dc.subject.emtree | Beta tubulin | en_US |
dc.subject.emtree | Choline | en_US |
dc.subject.emtree | Choline kinase | en_US |
dc.subject.emtree | Choline phosphate cytidylyltransferase | en_US |
dc.subject.emtree | Cholinephosphotransferase | en_US |
dc.subject.emtree | Cytidine diphosphate | en_US |
dc.subject.emtree | Cytidine triphosphate | en_US |
dc.subject.emtree | Docosahexaenoic acid | en_US |
dc.subject.emtree | Dopamine | en_US |
dc.subject.emtree | Glutamate receptor 1 | en_US |
dc.subject.emtree | Icosapentaenoic acid | en_US |
dc.subject.emtree | Neurofilament protein | en_US |
dc.subject.emtree | Neurotransmitter | en_US |
dc.subject.emtree | Neurotransmitter receptor | en_US |
dc.subject.emtree | Omega 3 fatty acid | en_US |
dc.subject.emtree | Phospholipid | en_US |
dc.subject.emtree | Postsynaptic density protein 95 | en_US |
dc.subject.emtree | Synapsin I | en_US |
dc.subject.emtree | Syntaxin | en_US |
dc.subject.emtree | Syntaxin 3 | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Uridine | en_US |
dc.subject.emtree | Uridine phosphate | en_US |
dc.subject.emtree | Acetylcholine release | en_US |
dc.subject.emtree | Alzheimer disease | en_US |
dc.subject.emtree | Animal behavior | en_US |
dc.subject.emtree | Behavior modification | en_US |
dc.subject.emtree | Brain cell | en_US |
dc.subject.emtree | Brain function | en_US |
dc.subject.emtree | Brain injury | en_US |
dc.subject.emtree | Degenerative disease | en_US |
dc.subject.emtree | Dendritic spine | en_US |
dc.subject.emtree | Diet supplementation | en_US |
dc.subject.emtree | Dopamine release | en_US |
dc.subject.emtree | Drug bioavailability | en_US |
dc.subject.emtree | Drug dose comparison | en_US |
dc.subject.emtree | Drug metabolism | en_US |
dc.subject.emtree | Drug uptake | en_US |
dc.subject.emtree | Editorial | en_US |
dc.subject.emtree | Gerbil | en_US |
dc.subject.emtree | Guman | en_US |
dc.subject.emtree | Mammal cell | en_US |
dc.subject.emtree | Nerve cell plasticity | en_US |
dc.subject.emtree | Neurochemistry | en_US |
dc.subject.emtree | Neurotransmitter release | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Phospholipid synthesis | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Signal transduction | en_US |
dc.subject.emtree | Stroke | en_US |
dc.subject.emtree | Synapse | en_US |
dc.subject.emtree | Synaptic transmission | en_US |
dc.subject.emtree | Synaptogenesis | en_US |
dc.subject.mesh | Administration | en_US |
dc.subject.mesh | Oral | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Brain | en_US |
dc.subject.mesh | Brain diseases | en_US |
dc.subject.mesh | Cell membrane | en_US |
dc.subject.mesh | Choline | en_US |
dc.subject.mesh | Docosahexaenoic acids | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Membrane lipids | en_US |
dc.subject.mesh | Phospholipids | en_US |
dc.subject.mesh | Prodrugs | en_US |
dc.subject.mesh | Synapses | en_US |
dc.subject.mesh | Synaptic transmission | en_US |
dc.subject.mesh | Uridine | en_US |
dc.subject.scopus | Choline Phosphate Cytidylyltransferase; Phosphatidylcholines; Citicoline | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.title | Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses | en_US |
dc.type | Article |